DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Silver Spring  MD  20993

NDA 210491

NDA APPROVAL

Vertex Pharmaceuticals Inc.
50 Northern Ave.
Boston, MA 02210

Attention:  Charlotte Heyman, MSc
          Senior Manager, Global Regulatory Affairs

Dear Ms. Heyman:

Please refer to your New Drug Application (NDA) dated June 28, 2017, received June 28, 2017,
and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic
Act (FDCA) for Symdeko (tezacaftor/ivacaftor) Tablets 100/150 mg.

This new drug application provides for the use of Symdeko (tezacaftor/ivacaftor) tablets for the
treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for
the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro
data and/or clinical evidence.

We have completed our review of this application, as amended.  It is approved, effective on the
date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of
labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
automated drug registration and listing system (eLIST), as described at
of labeling must be identical to the enclosed labeling (text for the prescribing information, text
for the patient package insert).  Information on submitting SPL files using eLIST may be found
in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As,
available at
CM072392.pdf

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS
Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3).* For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 210491.**” Approval of this submission by FDA is not required before the labeling is used.

**EXPIRATION DATING PERIOD**

The provided information supports the approval of the applicant requested drug product expiry of 30 months.

**RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER**

Your request for a rare pediatric disease priority review voucher has been denied. You did not qualify for the voucher, because your application did not meet the requirements to be a “rare pediatric disease product application” for the following reason:

> Your application did not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population. See section 529(a)(4)(D) of the Federal Food, Drug & Cosmetic Act (21 U.S.C. § 360ff(a)(4)(D)). Your application, and this approval, instead relied on clinical data derived from studies that examined an adult population, albeit with the inclusion of some pediatric subjects age 12 and above.

**ADVISORY COMMITTEE**

Your application for tezacaftor/ivacaftor was not referred to an FDA advisory committee because the application did not raise significant public health questions on the role of the drug/biologic in the diagnosis, cure, mitigation, treatment, or prevention of a disease

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.
PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the prescribing information, Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the prescribing information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologies qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm.

POST APPROVAL FEEDBACK MEETING

Reference ID: 4220295
New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Jessica Lee, Regulatory Project Manager, at (301) 796-3769.

Sincerely,

{See appended electronic signature page}

Curtis J. Rosebraugh, MD, MPH
Director
Office of Drug Evaluation II
Office of New Drugs
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CURTIS J ROSEBRAUGH
02/12/2018